FIG A2.

Adjusted mean change from baseline over 24 weeks in EORTC QLQ-C30 functioning domains. Adjusted mean change from baseline was calculated using an MMRM analysis including treatment, visit, and treatment-by-visit interaction as explanatory variables and the baseline score as a covariate. Data reported are the adjusted mean change from baseline averaged over 24 weeks. Error bars represent the 95% CIs. Dotted lines represent the threshold for clinically meaningful change (an absolute change ≥10 points from baseline). EORTC, European Organization for Research and Treatment of Cancer; MMRM, mixed-effect model repeated measures; QLQ-C30, 30-item Quality of Life Questionnaire; STRIDE, Single Tremelimumab Regular Interval Durvalumab.